TABLE 1.

Baseline characteristics of study subjects according to treatment group

CharacteristicaHIV-1-seronegative subjectsHIV-1-seropositive subjects
Group A (Fluad) (n = 81)Group B (Agrippal) (n = 80)Group C (Fluad) (n = 46)Group D (Agrippal) (n = 49)
Mean yrs of age (SD)31.4 (7.5)32.5 (7.1)41.0 (5.7)40.1 (6.4)
No. (%) of subjects
    Male66 (81.5)71 (88.7)40 (86.9)39 (79.6)
    Previously vaccinated for influenza20 (24.7)22 (27.5)22 (47.8)19 (38.7)
    On HAART29 (63.0)39 (79.6)
Baseline no. (SD) of:
    HIV-1 RNA copies/ml2,809 (9,736)19,608 (56,471)
    CD4+ cells/mm3398 (216)413 (197)
No. (%) at CDC stage:
    A6 (22.2)8 (26.6)
    B17 (62.9)20 (66.6)
    C4 (14.8)2 (6.6)
  • a HAART, highly active antiretroviral therapy. HIV-1 RNA level, CD4+ cell count, and CDC disease stage refer to HIV-1-infected individuals enrolled in the subsets (27 individuals in group C and 30 individuals in group D).